Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection?
1Department of Cardiology, Gentofte Hospital, Denmark.
Journal of Atrial Fibrillation
|December 14, 2016
Summary
Cardiac resynchronization therapy (CRT) benefits heart failure patients, but guidelines exclude complex cases. This review examines how comorbidities impact CRT effectiveness in real-world patients.
Area of Science:
- Cardiology
- Heart Failure Management
- Medical Device Therapy
Background:
- Cardiac resynchronization therapy (CRT) is proven to improve outcomes in selected heart failure patients.
- Clinical trials often exclude patients with significant comorbidities, limiting guideline applicability to real-world scenarios.
- Managing complex heart failure patients with comorbidities presents a challenge for CRT device selection.
Approach:
- This review synthesizes data from clinical trials and observational studies.
- It specifically analyzes the impact of comorbidities on CRT efficacy.
- The goal is to inform patient selection for CRT in diverse populations.
Key Points:
- Comorbidities can influence the effectiveness of CRT.
- Real-world patient populations differ significantly from those in landmark clinical trials.
- Understanding comorbidity effects is crucial for optimizing CRT patient selection.
Conclusions:
- Current guidelines may not fully address the nuances of CRT in patients with multiple health issues.
- Further research is needed to refine CRT selection criteria for complex heart failure patients.
- Personalized approaches are essential for maximizing CRT benefits in comorbid individuals.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
695
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
695
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
603
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
603
01:29Cardiomyopathy V: Interprofessional Care
566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
706
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
706
01:30Heart Failure IV: Classification and Diagnostic Evaluation
510
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
510
01:22Heart Failure VI: Adjunct Therapies
494
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
494